Use of methotrexate for autoimmune hearing loss

O. Tirzaman, Jan Kasperbauer, Eric Lawrence Matteson, G. W. Facer, C. W. Beatty, D. A. Fabry, T. J. McDonald

Research output: Contribution to journalArticle

35 Citations (Scopus)

Abstract

To assess the efficacy of low-dose methotrexate (MTX) given long-term for the treatment of autoimmune hearing loss, we performed a prospective open-label study of 11 patients with treatment-refractory autoimmune hearing loss. All patients had ongoing episodic worsening of hearing in I or both ears before enrollment despite traditional medical therapy. The MTX dose was 7.5 to 17.5 mg/wk. Hearing loss and vertigo were evaluated at baseline and at completion of the study. Hearing improvement was defined as an improvement in the pure tone threshold (PT) average of >10 dB or an increase in speech discrimination (SD) of >15%, whereas worsening was defined as a worsening of >10 dB in PT or a decrease of >15% in SD in at least 1 ear. The MTX was well tolerated. Among the 6 patients with Meniere's disease, 4 had improvement or resolution of vertigo, while 2 had no improvement, Disequilibrium improved in all 3 patients with Cogan's syndrome. According to the parameters defined above, hearing improved in 9 patients (82%), was unchanged in 1 patient (9%), and worsened in 1 patient (9%). Long-term low-dose MTX therapy may be a useful therapy for some patients who have hearing loss with a presumptively autoimmune-mediated component that is refractory to traditional therapies.

Original languageEnglish (US)
Pages (from-to)710-714
Number of pages5
JournalAnnals of Otology, Rhinology and Laryngology
Volume109
Issue number8 I
StatePublished - 2000

Fingerprint

Hearing Loss
Methotrexate
Hearing
Speech Perception
Vertigo
Ear
Cogan Syndrome
Therapeutics
Meniere Disease

Keywords

  • Autoimmune hearing loss
  • Cogan's syndrome
  • Meniere's disease
  • Methotrexate

ASJC Scopus subject areas

  • Otorhinolaryngology

Cite this

Tirzaman, O., Kasperbauer, J., Matteson, E. L., Facer, G. W., Beatty, C. W., Fabry, D. A., & McDonald, T. J. (2000). Use of methotrexate for autoimmune hearing loss. Annals of Otology, Rhinology and Laryngology, 109(8 I), 710-714.

Use of methotrexate for autoimmune hearing loss. / Tirzaman, O.; Kasperbauer, Jan; Matteson, Eric Lawrence; Facer, G. W.; Beatty, C. W.; Fabry, D. A.; McDonald, T. J.

In: Annals of Otology, Rhinology and Laryngology, Vol. 109, No. 8 I, 2000, p. 710-714.

Research output: Contribution to journalArticle

Tirzaman, O, Kasperbauer, J, Matteson, EL, Facer, GW, Beatty, CW, Fabry, DA & McDonald, TJ 2000, 'Use of methotrexate for autoimmune hearing loss', Annals of Otology, Rhinology and Laryngology, vol. 109, no. 8 I, pp. 710-714.
Tirzaman, O. ; Kasperbauer, Jan ; Matteson, Eric Lawrence ; Facer, G. W. ; Beatty, C. W. ; Fabry, D. A. ; McDonald, T. J. / Use of methotrexate for autoimmune hearing loss. In: Annals of Otology, Rhinology and Laryngology. 2000 ; Vol. 109, No. 8 I. pp. 710-714.
@article{5dd029309eb94afc82561c794a3183ce,
title = "Use of methotrexate for autoimmune hearing loss",
abstract = "To assess the efficacy of low-dose methotrexate (MTX) given long-term for the treatment of autoimmune hearing loss, we performed a prospective open-label study of 11 patients with treatment-refractory autoimmune hearing loss. All patients had ongoing episodic worsening of hearing in I or both ears before enrollment despite traditional medical therapy. The MTX dose was 7.5 to 17.5 mg/wk. Hearing loss and vertigo were evaluated at baseline and at completion of the study. Hearing improvement was defined as an improvement in the pure tone threshold (PT) average of >10 dB or an increase in speech discrimination (SD) of >15{\%}, whereas worsening was defined as a worsening of >10 dB in PT or a decrease of >15{\%} in SD in at least 1 ear. The MTX was well tolerated. Among the 6 patients with Meniere's disease, 4 had improvement or resolution of vertigo, while 2 had no improvement, Disequilibrium improved in all 3 patients with Cogan's syndrome. According to the parameters defined above, hearing improved in 9 patients (82{\%}), was unchanged in 1 patient (9{\%}), and worsened in 1 patient (9{\%}). Long-term low-dose MTX therapy may be a useful therapy for some patients who have hearing loss with a presumptively autoimmune-mediated component that is refractory to traditional therapies.",
keywords = "Autoimmune hearing loss, Cogan's syndrome, Meniere's disease, Methotrexate",
author = "O. Tirzaman and Jan Kasperbauer and Matteson, {Eric Lawrence} and Facer, {G. W.} and Beatty, {C. W.} and Fabry, {D. A.} and McDonald, {T. J.}",
year = "2000",
language = "English (US)",
volume = "109",
pages = "710--714",
journal = "Annals of Otology, Rhinology and Laryngology",
issn = "0003-4894",
publisher = "Annals Publishing Company",
number = "8 I",

}

TY - JOUR

T1 - Use of methotrexate for autoimmune hearing loss

AU - Tirzaman, O.

AU - Kasperbauer, Jan

AU - Matteson, Eric Lawrence

AU - Facer, G. W.

AU - Beatty, C. W.

AU - Fabry, D. A.

AU - McDonald, T. J.

PY - 2000

Y1 - 2000

N2 - To assess the efficacy of low-dose methotrexate (MTX) given long-term for the treatment of autoimmune hearing loss, we performed a prospective open-label study of 11 patients with treatment-refractory autoimmune hearing loss. All patients had ongoing episodic worsening of hearing in I or both ears before enrollment despite traditional medical therapy. The MTX dose was 7.5 to 17.5 mg/wk. Hearing loss and vertigo were evaluated at baseline and at completion of the study. Hearing improvement was defined as an improvement in the pure tone threshold (PT) average of >10 dB or an increase in speech discrimination (SD) of >15%, whereas worsening was defined as a worsening of >10 dB in PT or a decrease of >15% in SD in at least 1 ear. The MTX was well tolerated. Among the 6 patients with Meniere's disease, 4 had improvement or resolution of vertigo, while 2 had no improvement, Disequilibrium improved in all 3 patients with Cogan's syndrome. According to the parameters defined above, hearing improved in 9 patients (82%), was unchanged in 1 patient (9%), and worsened in 1 patient (9%). Long-term low-dose MTX therapy may be a useful therapy for some patients who have hearing loss with a presumptively autoimmune-mediated component that is refractory to traditional therapies.

AB - To assess the efficacy of low-dose methotrexate (MTX) given long-term for the treatment of autoimmune hearing loss, we performed a prospective open-label study of 11 patients with treatment-refractory autoimmune hearing loss. All patients had ongoing episodic worsening of hearing in I or both ears before enrollment despite traditional medical therapy. The MTX dose was 7.5 to 17.5 mg/wk. Hearing loss and vertigo were evaluated at baseline and at completion of the study. Hearing improvement was defined as an improvement in the pure tone threshold (PT) average of >10 dB or an increase in speech discrimination (SD) of >15%, whereas worsening was defined as a worsening of >10 dB in PT or a decrease of >15% in SD in at least 1 ear. The MTX was well tolerated. Among the 6 patients with Meniere's disease, 4 had improvement or resolution of vertigo, while 2 had no improvement, Disequilibrium improved in all 3 patients with Cogan's syndrome. According to the parameters defined above, hearing improved in 9 patients (82%), was unchanged in 1 patient (9%), and worsened in 1 patient (9%). Long-term low-dose MTX therapy may be a useful therapy for some patients who have hearing loss with a presumptively autoimmune-mediated component that is refractory to traditional therapies.

KW - Autoimmune hearing loss

KW - Cogan's syndrome

KW - Meniere's disease

KW - Methotrexate

UR - http://www.scopus.com/inward/record.url?scp=0033873783&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033873783&partnerID=8YFLogxK

M3 - Article

C2 - 10961801

AN - SCOPUS:0033873783

VL - 109

SP - 710

EP - 714

JO - Annals of Otology, Rhinology and Laryngology

JF - Annals of Otology, Rhinology and Laryngology

SN - 0003-4894

IS - 8 I

ER -